The Economics of Biosimilars: Improving Market Access, Sustainable Pricing and Reimbursement Policies

June 29, 2022 2:00pm

Sonia Oskouei
Vice President, Biosimilars
Cardinal Health

Chad A. Landmon
Partner
Axinn, Veltrop & Harkrider LLP

Juliana “Julie” Reed
Executive Director
The Biosimilars Forum

Mandy C. Leonard
Senior Director, Drug Use Policy and Formulary Management
Cleveland Clinic

Moderator:

Ali I. Ahmed
Senior Vice President, Biosimilars
Fresenius Kabi USA

  • Evaluating the clinical pipeline by company, indication and phase
    • Analyzing the market share for biosimilars in the United States
    • Target drugs with highest spending
    • Current market dynamics and considerations for biosimilar adoption
    • Comparing the European Union biosimilar experience
  • Considering the implications of insurers placing biosimilars on “primary tiers” and what that means for the future
  • Reviewing the implications of the House passed Lower Drug Costs Now Act
    • Understanding the implications of empowering the government to negotiate directly with manufacturers